Hunt talks through the phase IIa extension study of its human retinal progenitor cell therapy for degenerative eye disease.
ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy
Quick facts: ReNeuron Group PLC
Price: 110 GBX
Market Cap: £62.54 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE